The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470)
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
The G protein-coupled receptor 40 (GPR40) also known as free fatty acid receptor 1 (FFAR1) is highly expressed in pancreatic, islet β-cells and responds to endogenous fatty acids, resulting in amplification of insulin secretion only in the presence of elevated glucose levels. Hypothesis driven structural modifications to endogenous FFAs, focused on breaking planarity and reducing lipophilicity, led to the identification of spiropiperidine and tetrahydroquinoline acid derivatives as GPR40 agonists with unique pharmacology, selectivity, and pharmacokinetic properties. Compounds 1 (LY2881835), 2 (LY2922083), and 3 (LY2922470) demonstrated potent, efficacious, and durable dose-dependent reductions in glucose levels along with significant increases in insulin and GLP-1 secretion during preclinical testing. A clinical study with 3 administered to subjects with T2DM provided proof of concept of 3 as a potential glucose-lowering therapy. This manuscript summarizes the scientific rationale, medicinal chemistry, preclinical, and early development data of this new class of GPR40 agonists.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Free fatty acids regulate insulin secretion from pancreatic β cells through GPR40
Itoh, Y., Kawamata, Y., Harada, M., Kobayashi, M., Fujii, R., Fukusumi, S., Ogi, K., Hosoya, M., Tanaka, Y., Uejima, H., et al. (2003) · Nature · doi:10.1038/nature01478 · Cited by 1,538
Edfalk, S., Steneberg, P., & Edlund, H. (2008) · Diabetes · doi:10.2337/db08-0307 · Cited by 587
A human cell surface receptor activated by free fatty acids and thiazolidinedione drugs
Kotarsky, K., Nilsson, N. E., Flodgren, E., Owman, C., & Olde, B. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)03064-4 · Cited by 352
Parker, H. E., Habib, A. M., Rogers, G. J., Gribble, F. M., & Reimann, F. (2009) · Diabetologia · doi:10.1007/s00125-008-1202-x · Cited by 324
Fujiwara, K., Maekawa, F., & Yada, T. (2005) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00035.2005 · Cited by 253
Burant, C. F., Viswanathan, P., Marcinak, J., Cao, C., Vakilynejad, M., Xie, B., & Leifke, E. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61879-5 · Cited by 244
Role of GPR40 in fatty acid action on the β cell line INS-1E
Shapiro, H., Shachar, S., Sekler, I., Hershfinkel, M., & Walker, M. D. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.07.042 · Cited by 220
Cited by
Spirocyclic Scaffolds in Medicinal Chemistry
Hiesinger, K., Dar’in, D., Proschak, E., & Krasavin, M. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01473 · Cited by 618
Xiong, B., Wang, Y., Chen, Y., Xing, S., Liao, Q., Chen, Y., Li, Q., Li, W., & Sun, H. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00910 · Cited by 232
Self-citationG Protein–Coupled Receptors Targeting Insulin Resistance, Obesity, and Type 2 Diabetes Mellitus
Riddy, D. M., Delerive, P., Summers, R. J., Sexton, P. M., & Langmead, C. J. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014373 · Cited by 108
“…agonists developed by Eli Lilly, including LY2881835 and LY2922470, are in phase I and reduce hyperglycemia and increase GLP-1 secretion in both rats and humans (Mittermayer et al., 2015; Hamdouchi et al., 2016), suggesting that these compounds may still prove beneficial for the treatment of T2DM.”
Background
Metadata
- Authors
- Hamdouchi, C., Kahl, S. D., Patel Lewis, A., Cardona, G. R., Zink, R. W., Chen, K., Eessalu, T. E., Ficorilli, J. V., Marcelo, M. C., Otto, K. A., Wilbur, K. L., Lineswala, J. P., Piper, J. L., Coffey, D. S., Sweetana, S. A., Haas, J. V., Brooks, D. A., Pratt, E. J., Belin, R. M., Deeg, M. A., Ma, X., Cannady, E. A., Johnson, J. T., Yumibe, N. P., Chen, Q., Maiti, P., Montrose-Rafizadeh, C., Chen, Y., & Reifel Miller, A.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2016-11-11
- Volume
- 59
- Issue
- 24
- Pages
- 10891-10916
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2532977935
- Cited by
- 62
- References
- 7
- FWCI
- 7.79
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470). https://app.cochat.ai/papers/10.1021/acs.jmedchem.6b00892
- The paper
- Hamdouchi, C., Kahl, S. D., Patel Lewis, A., Cardona, G. R., Zink, R. W., Chen, K., Eessalu, T. E., Ficorilli, J. V., Marcelo, M. C., Otto, K. A., Wilbur, K. L., Lineswala, J. P., Piper, J. L., Coffey, D. S., Sweetana, S. A., Haas, J. V., Brooks, D. A., Pratt, E. J., Belin, R. M., . . . Reifel Miller, A. (2016). The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470). Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.6b00892
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.